Prognostic value of S-phase fraction in 920 breast cancer patients: Focus on T1N0 status

International Journal of Biological Markers

Volumn 18, Issue 4, 2003, Pages 273-279

  Largillier, R ^a   Namer, M ^a   Ramaioli, A ^a   Ferrero, J M ^a   Magne N ^a   Courdi, A ^a   Leblanc Talent, P ^a   Formento, P ^a   Ettore, F ^a   Milano, Gérard ^a  

^a CENTRE ANTOINE LACASSAGNE   (France)

Author keywords

Breast cancer; Prognostic markers; S phase fraction

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ESTRADIOL RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGE; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; BREAST SURGERY; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER SURVIVAL; CELL CYCLE S PHASE; CELL FRACTIONATION; CELL KINETICS; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PROGNOSIS; RISK ASSESSMENT; TUMOR CELL; TUMOR VOLUME;

EID: 10744228425     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2008.506     Document Type: Article

References (50)

1. Fisher B, Dignam J, Tan-Chiu E, et al. Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes. J Natl Cancer Inst 2001; 93: 112-20.
2. Sheldon JM, Fetting JH, Siminoff LA. Offering the option of randomized clinical trials to cancer patients who overestimate their prognoses with standard therapies. Cancer Invest 1993; 11: 57-62.
3. Fetting JH, Siminoff LA, Piantadosi S, Abeloff MD, Damron DJ, Sarsfield AM. Effect of patients expectations of benefit with standard breast cancer adjuvant chemotherapy on participation in a randomized clinical trial: a vignette study. J Clin Oncol 1990; 8: 1476-82.
4. Ravdin PM, Siminoff LA, Davis GJ, et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001; 19: 980-91.
5. Fisher ER, Costantino J, Fisher B, Redmond C. Pathologic finding from the National Surgical Adjuvant Breast Project (protocol 4): discriminants for 15-year survival. Cancer 1993; 71: 2141-50.
6. Rosen PP, Groshen S, Saigo PE, Kinne DW, Hellman S. Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: a study of 644 patients with median follow-up of 18 years. J Clin Oncol 1989; 7: 1239-51.
7. Rosner D, Lane WW. Should all patients with node-negative breast cancer receive adjuvant therapy? Identifying additional subsets of low-risk patients who are highly curable by surgery alone. Cancer 1991; 68: 1482-94.
8. Loprinzi CL, Thome SD. Understanding the utility of adjuvant systemic therapy for primary breast cancer. J Clin Oncol 2001; 19: 972-9.
9. Volpi A, De Paola F, Nanni O, et al. Prognostic significance of biologic markers in node-negative breast cancer patients: a prospective study. Breast Cancer Res Treat 2000; 63: 181-92.
10. Broët P, Romain S, Daver A, et al. Thymidine kinase as a proliferative marker: clinical relevance in 1,692 primary breast cancer patients. J Clin Oncol 2001; 19: 2778-87.
11. Romain S, Bendahl PO, Guirou O, Malmstrom P, Martin PM, Ferno M. DNA-synthesizing enzymes in breast cancer (thymidine kinase, thymidylate synthase and thymidylate kinase): association with flow cytometric S-phase fraction and relative prognostic importance in node-negative premenopausal patients. Int J Cancer 2001; 95: 56-61.
12. Scarff RW, Torloni H. Histological typing of breast tumors. Geneva: World Health Organization 1968; 13-20.
13. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19: 403-10.
14. Milano G, Moll JL, Formento JL, et al. Simultaneous micro measurement of steroid receptors in breast cancer. Br J Cancer 1983; 48: 579-84.
15. Romain S, Formento JL, Guirou O, Francoual M, Milano G, Martin PM. Determination of oestrogen receptors by enzyme immunoassay. Technical differences between laboratories and their consequences. Eur J Cancer 1994; 30: 740-6.
16. Blankenstein MA. Comparison of ligand binding assay and enzyme immunoassay of estrogen receptor in human breast cancer cytosols. Experience of the EORTC receptor group. Breast Cancer Res Treat 1990; 17: 91-8.
17. Vindelov LL, Christensen IJ, Nissen NI. A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 1983; 3: 323-7.
18. Courdi A, Hery M, Dahan E, et al. Factors affecting relapse in node-negative breast cancer. A multivariate analysis including the labeling index. Eur J Cancer Clin Oncol 1989; 25: 351-6.
19. Kute TE, Quadri Y, Muss H, et al. Flow cytometry in node-positive breast cancer: Cancer and Leukemia Group B protocol 8869. Cytometry 1995; 22: 297-306.
20. Spyratos F, Briffod M, Tubiana-Hulin M, et al. Sequential cytopunctures during preoperative chemotherapy for primary breast carcinoma. II. DNA flow cytometry changes during chemotherapy, tumor regression, and short-term follow-up. Cancer 1992; 69: 470-5.
21. Remvikos Y, Jouve M, Beuzeboc P, Viehl P, Magdelénat H, Pouillart P. Cell cycle modifications of breast cancers during neoadjuvant chemotherapy: a flow cytometry study on fine needle aspirates. Eur J Cancer 1993; 29: 1843-8.
22. Stal O, Skoog L, Rutqvist LE, et al. S-phase fraction and survival benefit from adjuvant chemotherapy or radiotherapy of breast cancer. Br J Cancer 1994; 70: 1258-62.
23. Gamel JW, Meyer JS, Province MA. Proliferative rate by S-phase measurement may affect cure of breast carcinoma. Cancer 1995; 76: 1009-18.
24. Hietanen P, Blomqvist C, Wasenius VM, Niskanen E, Franssila K, Nordling S. Do DNA ploidy and S-phase fraction in primary tumour predict the response to chemotherapy in metastatic breast cancer? Br J Cancer 1995; 71: 1029-32.
25. Chevillard S, Lebeau J, Pouillart P, et al. Biological and clinical significance of concurrent p53 gene alterations, MDR1 gene expression, and S-phase fraction analyses in breast cancer patients treated with primary chemotherapy or radiotherapy. Clin Cancer Res 1997; 3: 2471-8.
26. Dutrillaux B, Gerbault-Seureau M, Remvikos Y, Zafrani B, Prieur M. Breast cancer genetic evolution. I. Data from cytogenetics and DNA content. Breast Cancer Res Treat 1991; 19: 245-55.
27. Kallioniemi OP, Blanco G, Alavaikko M, et al. Improving the prognostic value of DNA flow cytometry in breast cancer by combining DNA index and S-phase fraction. A proposed classification of DNA histograms in breast cancer. Cancer 1988; 61: 2183-90.
28. O'Reilly SM, Camplejohn RS, Millis RR, Rubens RD, Richards MA. Proliferative activity, histological grade and benefit from adjuvant chemotherapy in node positive breast cancer. Eur J Cancer 1990; 26: 1035-8.
29. Ewers SB, Attewell R, Baldetorp B, Borg A, Langstrom E, Killander D. Prognostic potential of flow cytometric S-phase and ploidy prospectively determined in primary breast carcinomas. Breast Cancer Res Treat 1992; 20: 93-108.
30. Gnant MF, Blijham G, Reiner A, et al. DNA ploidy and other results of DNA flow cytometry as prognostic factors in operable breast cancer: 10 year results of a randomised study. Eur J Cancer 1992; 28: 711-6.
31. Shankey TV, Rabinovitch PS, Bagwell B, et al. Guidelines for implementation of clinical DNA cytometry. Cytometry 1993; 14: 472-7.
32. Remvikos Y, Mosseri V, Asselain B, et al. S-phase fractions of breast cancer predict overall and post-relapse survival. Eur J Cancer 1997; 33: 581-6.
33. Wenger CR, Clark GM. S-phase fraction and breast cancer: a decade of experience. Breast Cancer Res Treat 1998; 51: 255-65.
34. Bryant J, Fisher B, Gunduz N, Costantino JP, Emir B. S-phase fraction combined with other patient and tumor characteristics for the prognosis of node-negative, estrogen-receptor-positive breast cancer. Breast Cancer Res Treat 1998; 51: 239-53.
35. Pinto AE, Andre S, Soares J. Short-term significance of DNA ploidy and cell proliferation in breast carcinoma: a multivariate analysis of prognostic markers in a series of 308 patients. J Clin Pathol 1999; 52: 604-11.
36. Michels JJ, Duigou F, Marnay J. Flow cytometry in primary breast carcinomas. Prognostic impact of proliferative activity. Breast Cancer Res Treat 2000; 62: 117-26.
37. Pinto AE, Andre S, Pereira T, Nobrega S, Soares J. Prognostic comparative study of S-phase fraction and Ki-67 index in breast carcinoma. J Clin Pathol 2001; 54: 543-9.
38. Malmström P, Bendahl PO, Boiesen P, Brünner N, Idvall I, Fernö M. S-phase fraction and urokinase plasminogen activator are better markers for distant recurrences than Nottingham prognostic index and histologic grade in a prospective study of premenopausal lymph node-negative breast cancer. J Clin Oncol 2001; 19: 2010-9.
39. Chassevent A, Jourdan ML, Romain S, et al. S-phase fraction and DNA ploidy in 663 T1T2 breast cancers: a standardized flow cytometric study. Clin Cancer Res 2001; 7: 909-17.
40. Bagwell CB, Clark GM, Spyratos F, et al. Optimizing flow cytometric DNA ploidy and S-phase fraction as independent prognostic markers for node-negative breast cancer specimens. Cytometry 2001; 46: 121-35.
41. Jourdan ML, Ferrero-Pous M, Spyratos F, Romain S, Martin PM, Chassevent A. Flow cytometric S-phase fraction measurement in breast carcinoma: influence of software and histogram resolutions. Cytometry 2002; 48: 66-70.
42. Romain S, Martin PM, Klijn JGM, et al. DNA synthesis enzyme activity: a biological tool useful for predicting antimetabolic drug sensitivity in breast cancer? Int J Cancer 1997; 74: 156-61.
43. Foekens JA, Romain S, Look MP, Martin PM, Klijn JGM. Thymidine kinase and thymidylate synthetase in advanced breast cancer: response to tamoxifen and chemotherapy. Cancer Res 2001; 61: 1421-5.
44. Michels JJ, Duigou F, Marnay J, et al. Flow cytometry and quantitative immunohistochemical study of cell cycle regulation proteins in invasive breast carcinoma: prognostic significance. Cancer 2003; 97: 1376-86.
45. Chang J, Clark GM, Allred DC, Mohsin S, Chamness G, Elledge RM. Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor. Cancer 2003; 97: 545-53.
46. Daidone MG, Silvestrini R. Prognostic and predictive role of proliferation indices in adjuvant therapy of breast cancer. J Natl Cancer Inst 2001; 30: 27-35.
47. Pinto AE, Andre S, Pereira T, Nobrega S, Soares J. Prognostic comparative study of S-phase fraction and Ki-67 index in breast carcinoma. J Clin Pathol 2001; 54: 543-9.
48. Simpson JF, Gray R, Dressler LG, et al. Prognostic value of histological grade and proliferative activity in axillary node-positive breast cancer: results from Eastern Cooperative Oncology Group comparison study, EST 4189. J Clin Oncol 2000; 18: 2059-69.
49. Paradiso A, Schittulli F, Cellamare G, et al. Randomized clinical trial of adjuvant fluorouracil, epirubicin, and cyclophosphamide chemotherapy for patients with fast-proliferating, node-negative breast cancer. J Clin Oncol 2001; 19: 3929-37.
50. Senderowicz AM, Sausville EA. Preclinical and clinical development of cyclin-dependent kinase modulators. J Natl Cancer Inst 2000; 92: 376-87.